Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovating the drug development process through an asset-centric research and development model. The company manages a diverse portfolio of therapeutics across several therapeutic areas, including SerpinPC for Hemophilia A and B, LB101 for solid tumors, ORX750 for Narcolepsy Type 1 and other sleep disorders, and MGX292 for pulmonary arterial hypertension. Each therapeutic program is developed by a dedicated subsidiary, leveraging a centralized infrastructure and experienced management team to ensure efficient advancement of its pipeline assets.
Janpix Ltd. is a biopharmaceutical company focused on the development of innovative cancer treatments through the discovery of inhibitors targeting Signal Transducer and Activator of Transcription (STAT) proteins. Founded in 2017 and based in Cambridge, Massachusetts, with a research facility in Mississauga, Canada, Janpix aims to address the challenges associated with inhibiting STAT proteins, particularly STAT3 and STAT5, which are linked to various cancers. The company has developed ultra-selective STAT inhibitors that not only target hematological tumors and glioblastomas but also modulate immune cells and the tumor microenvironment to enhance cancer eradication. Janpix's research is driven by the goal of providing effective treatment options for patients facing these complex diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.